Clinical Trial: A Phase 1 Study in Patients With Metastatic Castration-Resistant Prostate Cancer

U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07719361) titled 'A Phase 1 Study in Patients With Metastatic Castration-Resistant Prostate Cancer' on July 17.

Brief Summary: The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC). It will also study the drug's pharmacokinetics (how the body breaks down FX-111) and how well FX-111 treats mCRPC. The main questions it aims to answer are:

What are the side effects of FX-111?

Does FX-111 work to reduce or prevent progression of mCRPC?

The study doctor will oversee participants' treatment with FX-111 and ask about any sid...